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Background: Conversion disorder (CD) or functional neurological disorder (FND) affects at least 
764,000 people in the UK per year. As its origin is unknown and treatment has limited effects the 
condition forms a high individual and societal burden and clinically-unmet need. Research aiming to 
improve the outlook for people with this condition is urgently required. Exploration of the role of 
stress response and systemic low-grade inflammation(SLI) in CD/FND is warranted. The first step is to 
establish the feasibility of identifying, recruiting and assessing a clinical cohort of CD/FND patients for 
biomarkers of SLI, in addition to objective and subjective measures of stress and related factors. 
Methods: The settings are currently clinics and services within the Tees, Esk and Wear Valleys NHS 
Foundation Trust (TEWV). Phase 1 and phase 3 of our work are described in this paper, assessing the 
feasibility of assessing a cohort of CD/FND patients. Ethical approval has been granted for this study. 
The study will use observational measures including a blood sample for assessment of inflammation 
biomarkers; hair cortisol testing; self-report measures of stress, childhood trauma and health; 
targeted neurocognitive functioning and psychiatric examination. The findings will be used to inform 
future phases of our work.
Discussion: Study outcomes will be knowledge about levels of SLI, psychological and cognitive 
symptoms in patients with CD/FND that is so far largely unknown. Knowledge regarding the feasibility 
of conducting a study in this population will also be gained. This will enable a comprehensive testing 
and evaluation of the proposed processes of recruitment, retention and data collection.   This is hoped 
to lay the groundwork for future work leading to the development of novel treatments for CD/FND 
patients.
Keywords: Conversion Disorder; Functional Neurological Disorder; Inflammation; Stress; Cognitive 
function; Adverse Childhood Experience; Feasibility; Protocol
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Background 
1.1 Background and Rationale
Conversion disorder (CD) or functional neurological disorder affects at least 764,000 people in the UK 
per year.  It leads to long-term distress, disability, diminished quality of life and consequent demand 
on health care services (1).  As its origin is unknown(2) and treatment has limited effects (3-5), this 
condition forms a high individual and societal burden and clinically-unmet need.  Research aiming to 
improve the outlook for people with this condition is urgently needed. 
The theoretical model implicating stress response and systemic low-grade inflammation (SLI) in the 
development of mental disorders is gaining ground(6-11), implying SLI activity resulting in sickness 
behaviour (fatigue, mood and cognitive symptoms) that, if prolonged, may provoke stress-related 
mental disorders (6) such as depression and Post Traumatic Stress Disorder (PTSD) (7-9). 
CD is often stress-related (10) but associated with functional neurological and cognitive problems, not 
with mood symptoms(11). Recent functional neuroimaging (fMRI) studies suggest brain alterations in 
the emotion-motor processing in people with motor CD (12, 13) that result in functional neurological 
symptoms, not in depression or Post Traumatic Stress Disorder(PTSD).   Focusing on CD with non-
seizure motor symptoms will provide us with an excellent opportunity to understand the pathogenic 
mechanism as basis for motor function mental disorders instead of mood disorders in relation to SLI 
and sickness behaviour. 
In a recent case study, treatment of subjective cognitive problems such as planning difficulties and 
mental slowness, resulted not only in improved cognitive functioning, but also improved motor 
symptoms (14).  Both motor and planning functions are represented in the cerebellum where many 
inflammatory receptors are also found. 
We want to explore the hypothesis that motor CD with neurocognitive symptoms such as planning 
problems is related to systemic low-grade inflammation (SLI) and that the cerebellum is involved in 
the pathogenic mechanism.  We envisage five steps for addressing this hypothesis: 
 Step 1: establish the feasibility of assessing a clinical cohort of up to 30 CD patients with motor 
symptoms for high sensitivity C-reactive protein (hsCRP), neurocognitive symptoms and biological 
(hair cortisol) and psychological signs of stress. 
 Step 2: develop a rodent model for CD focusing on (in) voluntary control motor deficits in relation 
to SLI and cerebellar involvement. 
 Step 3: if assessing a clinical cohort is feasible, and hsCRP scores compared to norm scores indicate 
SLI in CD, establish the role of cytokines and microRNA in the pathogenesis of CD. 
 Step 4: should the rodent model confirm a link between cerebellar inflammation and (in) voluntary 
motor symptoms, assess cerebellar function in CD patients by fMRI. 
 Step 5: depending on outcome of earlier steps, evaluate an anti-inflammatory intervention in CD 
with motor symptoms. 
This Protocol is for step 1 and step 3, the feasibility study, the results of which will inform the further 
steps by providing us with knowledge about levels of SLI, psychological and cognitive symptoms in 
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patients with CD that so far is lacking and enable a comprehensive testing and evaluation of the 
proposed processes of recruitment, retention and data collection.  
1.2 Objectives
This study will explore the feasibility of recruiting and retaining a cohort of participants with a disabling 
disorder and collecting data through psycho-diagnostic testing, clinical lab and neurocognitive testing. 
We will include an evaluation of the costs associated with recruitment, retention and analysis to 
inform the next steps of the research and to meet the following specific aims:
 To establish the feasibility of assessing a clinical cohort of CD patients for biomarkers of SLI such 
as complete blood counts and high sensitivity C-reactive protein (hsCRP), inflammation-associated 
microRNAs (miR-146a, miR-155, miR-223, miR-21, and miR-132), cytokines (TNF, IL1b, IL6, IFNg, 
VEGF and ANG2) and hair cortisol (15) as well as psychological signs of stress.  
 To establish the feasibility of identifying, recruiting and retaining participants from this patient 
group and to determine the acceptability of the study processes.
A further objective of this study is to establish a Patient and Public Involvement (PPI) advisory group. 
All participants in the study will be invited to provide feedback on study procedures and patient 
materials as part of the study, but in addition we would like to recruit interested people with lived 
experience of the condition to advise on and contribute to dissemination of the study findings and the 
design and management of future research projects.  
Methods
2.1 Study setting
It is anticipated that the majority of participants will be recruited through clinics and services within 
the Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV).  Other services that may be involved 
are Humberside Trust, the Neurology Dept. of York Teaching Hospital and GP practices in Yorkshire.
2.2 Inclusion criteria
Our target population will be adult patients, aged 18 and above with diagnosed or suspected 
functional neurological disorders/conversion disorders with motor symptoms. Both incident and 
prevalent cases will be included.  
2.3 Exclusion criteria
The exclusion criteria includes patients with a diagnosis of Cushings syndrome, any blood-clotting 
disorders (e.g. haemophilia) or transfusion transmissible infections (e.g. HIV); the use of steroidal 
medication; patients with non-motor conversion disorder, and patients with pseudo-seizures as well 
as epileptic seizures.  We will also exclude patients with brain injury or neuro-degenerative conditions 
such as dementia or Parkinsons disease.  Also, for this feasibility stage, patients who are not able to 
complete self-administered questionnaires in English will be excluded.
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Patient eligibility is determined by a checklist completed by medics. This process is shown in the 
flowchart below.
- insert figure 1 here-
2.4 Recruitment 
An information leaflet about the study will be circulated to clinicians and colleagues within the 
participating NHS trusts who may be providing care for this patient group and who may be interested 
in introducing the study to their patients.   It will be made clear that there is no expectation that they 
participate in the study.  Interested Health Care Professionals (HCPs) will be invited to contact the 
study team should they want further information about the study
Other recruitment options will also be explored including GP practices and the neurology and 
emergency departments of hospital trusts and mental health trusts as mentioned above.  Should this 
be feasible, participating community mental health teams [CMHTs) and GP practices will, where 
possible, identify potential participants through electronic searches; in addition to which GPs and 
other health professionals will be able to introduce the study to suitable patients during a 
consultation.  
2.5 Procedures
In any of the above settings the clinician, nurse, GP or other healthcare provider (HCP) can introduce 
the study, give or send the patient an invitation letter with a copy of the patient information sheet 
and invite the patient to complete a Permission for release of personal contact details form which 
would be securely faxed or emailed to the research team.  A nurse or suitably-qualified researcher will 
contact the patient by telephone to answer any questions and arrange a face-to-face appointment 
with the potential participant at his/her home or preferred suitable location, to confirm capacity and 
eligibility, and, if the patient is happy to go ahead and eligible, take informed consent.  
Consenting participants will be invited to complete the baseline questionnaires. Researchers will invite 
feedback on the time taken to complete the questionnaires and whether the task presented any 
problems, to help the research team assess patient burden.  Blood and hair samples, together with 
blood pressure and height, weight and waist measurements, will be taken either at the baseline visit 
or the follow-up appointment according to patient preference.   
Study researchers will also arrange an appointment for the participant to attend the follow-up session 
for neuro-cognitive tests and psychiatric examination, in an NHS or University of York setting.  This 
examination will provide participants with an expert opinion on their condition. 
All participants will continue to receive their usual care throughout the study. 
2.6 Participant Timeline




The feasibility of establishing the cohort and performing psycho-diagnostic assessment for description 
of the cohort indicating the relation between experienced stress and SLI will be assessed through the 
collection of the following data: 
2.7.1.1 Definition of the cohort 
Definition of the cohort will include a psychiatric examination using DSM-5 classification (11), 
Clinical Global Impression Scale (CGI) (16), Adverse Childhood Experiences (WHO-ACE-IQ) (17), 
Life Events Stress (LCU) (18). The perceived Stress Reactivity Scale (PSRS) (19) and Recent 
Perceived Stress Questionnaire (20) will also be completed and systolic and diastolic blood 
pressure and Body Mass Index (BMI) recorded.
2.7.1.2 Possible confounders 
Possible confounder of SLI such as chronic medical conditions (21) will be recorded in addition to: 
number of physical symptoms using an English version of the LKV(PSQ)(22), anxiety using the 
GAD7 (23) and depression using the PHQ9 (23) as well as the self-reported use of anti-
inflammatory medication at the point of recruitment to the study. 
2.7.1.3 Targeted neurocognitive functioning 
Assessment of neurocognitive functioning will be conducted using tools that have been found to 
be discriminative and reliable markers of change with improvement in CD [15]. i.e. mental 
slowness (14), divided attention (24); working memory [WAIS-IV](25).  Tests taken will be:
1. Digit span of the Wechsler Adult Intelligence Scale for working memory, forwards and 
backwards (25); 
2. Trail Making Test A and B for information processing and divided attention (24) taken from 
the Delis Kaplan Executive Functioning Scales.
3. Color-Word Interference Test (Stroop) for information processing and inhibition/attention 
(26) as part of the Delis Kaplan Scales.
4. Symbol Substitution (Coding) of the Wechsler Adult Intelligence Scale for information 
processing (25). 
5. Tower of London for executive functioning (27) as part of the Delis Kaplan Scales. 
2.7.1.4 High sensitivity C-Reactive protein
Characteristics of the proposed outcome measure (hsCRP) including standard deviation will be 
taken for future power calculation.  
2.7.1.5 Biomarkers of inflammation and stress 
Other biomarkers will be assessed including venepuncture for assessing total blood counts and 
hsCRP, and cortisol hair test as biomarker for chronic accumulative stress assessed by Anglia 
Ruskin University Biomarker lab (15). Blood and hair samples will be sent for analysis at 
participating trusts and assessed for clinical lab findings indicating SLI: complete blood counts and 
hsCRP [blood samples) and cortisol (hair) the results compared with norm scores.  
2.7.1.6 Inflammatory cytokines
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Targeted assessment of circulating inflammatory cytokines will be conducted based on how SLI 
has been measured in contexts within and beyond neurology (e.g. obesity, type one diabetes, 
ageing).  Cytokine (TNF, IL1b, IL6, IFNg, VEGF and ANG2) measurements combined with hsCRP 
results will give us a comprehensive view of our cohort to assess systemic inflammation.  
2.7.1.7 Micro RNAs
Targeted assessment of circulating (cell-free) inflammation-associated microRNAs based on how SLI 
has been measured in contexts within and beyond neurology (e.g. obesity, type one diabetes, ageing), 
including miR-146a, miR-155, miR-21, miR-223, and miR-132.
2.5.2 Secondary outcomes
The processes associated with the study will be assessed for acceptability to participants and health 
care providers, canvassing views of both. The numbers of patients identified through each of the 
recruitment methods and the proportion of those who were willing and eligible to take part will be 
recorded. Willingness to complete assessment processes will be monitored including, attrition rates 
and reasons, to identify any barriers to completion. Finally, the time and cost of data collection and 
analysis will also be assessed.
Data Management and Ethics
3.1 Approval
This study has been reviewed and approved by the NHS North West 11 Research Ethics Committee, 
Preston. IRAS nr. 261252
3.1 Confidentiality
All data will be handled in accordance with the UK Data Protection Act 1998. The Case Report Forms 
(CRFs) will not bear participant names. This data will be pseudo-anonymised using study identification 
numbers for identification. Data management activities will be described in a trial-specific Data 
Management Plan. Blood samples will be collected and processed in accordance with TEWV NHS 
Foundation Trust policies and procedures. Hair samples with be collected, stored and shipped in 
accordance with the protocols of the Anglia Ruskin Biomarker Laboratory who will be analysing the 
anonymised samples.
3.2 Ethical Issues
We are aware that people with disabling conditions represent a vulnerable group. However we do not 
anticipate any major ethical issues with the proposed study since there are no novel interventions and 
every effort will be made to keep the burden for patients as low as possible. 
The total assessment burden for patients will be one blood sample, taken at home or other suitable 
location by a nurse or other appropriately-qualified person and a selection of questionnaires that will 
take no more than 45 minutes to fill in.  Researchers will be aware of the need for breaks.
The psychiatric examination of 45 minutes, and the neurocognitive tests of 45 minutes will be 
arranged in a NHS setting and all travel costs will be reimbursed. 
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3.3 Risks and anticipated benefits for study participants and society
All participants will receive usual care.  No treatment will therefore be withheld by participating in this 
study. It is possible that in participating patients may benefit from the experts appraisal and 
treatment recommendations that may arise from the assessments.
3.4 Informing potential participants of possible benefits and known risks
The patient information leaflet will provide potential participants with information about the possible 
benefits and any known risks of taking part in the study.  Participants will be given the opportunity to 
discuss this issue with their clinician or study researcher prior to consenting to participate.  The 
researcher will inform the participant if new information comes to light that may affect the 
participants willingness to participate in the study. 
3.5 Research Governance
The study will be conducted to protect the human rights and dignity of the participant as reflected in 
the 1996 version of the Helsinki Declaration. Patients will not receive any financial inducement to 
participate. In order to protect participants the following provisions will be made/upheld; the study 
has been designed to minimise pain, discomfort and fear and any foreseeable risk in relation to the 
treatments involved, the explicit wishes of the participant will be respected including the right to 
withdraw from the study at any time, the interest of the patient will prevail over those of science and 
society, provision will be made for indemnity by the investigator and sponsor. The University of York 
has agreed to act as sponsor for the study.
3.6 Monitoring and reporting adverse events
This study will record details of any Serious Adverse Events [SAEs) that are required to be reported to 
the Research Ethics Committee [REC) under the terms of the Standard Operating Procedures for RECs. 
An SAE is defined as an untoward occurrence that: i) results in death; ii) is life threatening; iii) requires 
hospitalisation or prolongation of existing hospitalisation; iv) results in persistent or significant 
disability or incapacity; v) consists of a congenital anomaly or birth defect; or vi) is otherwise 
considered medically significant by the investigator.
Should a research participant experience a SAE we will report this to our main REC if in the opinion of 
the chief investigator the event was related (i.e. it resulted from administration of any of the research 
procedures) and unexpected. Reports of related and unexpected SAEs will be submitted within 15 
days of the chief investigator becoming aware of the event, using the appropriate form.
Study Management
4.1 Governance
In order to attain the objectives described above, we will develop an interdisciplinary project 
management structure with the co-applicants as governance board to address any issues in terms of 
feasibility that might arise during the project, and to ensure the future developments aimed at as 
described above. 
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A steering group consisting of CFC, JR, and SG will meet regularly and oversee producing the 
deliverables to target and time. Further involvement of NHS would enable us to build a network of 
collaborators, both clinical and preclinical, and of different specialisms such as psychiatry, neurology, 
nurses, psychotherapy and basic scientists. 
4.2 Deliverables
Findings of this study will be discussed with the research team, who will be involved in the follow up 
steps. Based on our discussion of the outcome of this feasibility study, we will then prepare grant 
proposals for follow up steps. A publication will also be prepared with regards to the feasibility 
outcomes.
4.3 Statement of Indemnity
NHS Indemnity procedures will apply.  The University of York will also provide relevant cover.  
4.4 Dissemination
A full dissemination plan will be drawn up in collaboration with the PPI group as it becomes 
established.  It is anticipated that this will include publication of the protocol and results and 
dissemination through patient and carer groups as well as conference presentations.  In addition the 
lead investigator will present the findings at the ICPM and EAPM conferences.
4.5 Study Status
The study is ongoing. Data collection commenced in August 2019 and is continuing. Data collection 
will be completed by mid-2020 and evaluation of the study processes will commence soon after.
Discussion
5.1 Relevance of expected findings
This study will be the first to our knowledge to i) assess stress-related SLI in CD/FND patients, and ii) 
establish the feasibility of the processes involved within this vulnerable population. It is therefore 
important for the development of work in CD/FND, and is the first step in an anticipated larger project 
aiming to develop new treatments for this population. 
It is envisaged that this study will provide knowledge about levels of SLI, psychological and cognitive 
symptoms in patients with CD/FND that is so far largely unknown. Furthermore it will provide valuable 
knowledge regarding the feasibility of conducting a study in these patients, including issues with 
recruitment, retention, data collection, and proposed procedural processes. This knowledge will 
enable a comprehensive testing and evaluation of the proposed processes involved in the study and 
will inform future study phases. 
More precisely, we would consider that creating a larger cohort is feasible if we would be able to 
recruit at least 60% of people approached for participation and if we can interest a variety of sites for 
participation, including sites outside mental health trusts, such as neurology, physiotherapy practices, 
and primary care sites. Also, there should be indications that the study procedures would be 
acceptable for patients, in terms of tolerance for the duration of interviews, the blood and hair 
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sampling and potentially distressing revisiting of past events, and willingness to attend psychiatric 
assessment. Data should be complete with an attrition rate not above 40%. Another aspect of 
feasibility would be that if we consider that inclusion or exclusion criteria might need to be refined, 
that these can be incorporated. Regarding the lab, feasibility would be expressed in if we succeed to 
get the required samples and to deliver them to the respective labs, with resulting valid lab outcomes. 
An ongoing issue is the classification of conditions such as CD in the research literature as there is a 
tendency in the international literature to introduce new classifications for this condition, that are 
sometimes of rather short duration. In the WHO ICD-10,(28) conversion disorder was the classification 
for this condition, with similar criteria as in the DSM IV and DSM-5(11). The DSM-5 term is conversion 
disorder/functional neurological disorder. In the development phase of the ICD-11, the term 
functional neurological disorder (FND)(29) made it into the Beta version of the ICD-11.(30) However, 
in the final ICD-11 version, this was abandoned in favour of the classification Dissociative neurological 
symptom disorder.(31,32) Also, there has been a controversy about whether this condition should be 
in the psychiatry or in the neurology section of the ICD-11. As collaboration between neurologists and 
psychiatrists is of the utmost importance, both in research and in clinical terms, such changes of 
terminology and envisioned ICD sections should preferably be avoided to support conducting 
internationally generalisable research into this condition that should withstand the comparison over 
time, unless compelling reasons would exist to make such adaptations. 
It has been suggested that somatoform disorders would gradually be classified otherwise pending 
their further understanding of pathogenic mechanism, or clear-cut treatment implications related to 
a new diagnostic classification.(33) However, for conversion disorder, as the literature stands now, 
there is no such rationale to change the classification, not in terms of pathogenic mechanisms, and 
not in terms of available treatment modes. Hence from a clinical epidemiological research  
perspective, it would be preferable to stick with existing classifications whilst we continue to try to 
understand this condition better, in, preferably, interdisciplinary research efforts. For future research, 
in view of this shift in classifications, a thorough phenomenological description of the symptoms 
experienced by the patients and observed by doctors and other health care professionals becomes of 
the utmost importance, in order to enable researchers and clinicians from different backgrounds to 
understand which patients and conditions we explore. For this purpose, we use the following table, 
which enables us to describe the phenomenology in a detailed manner, from the perspective of 
possible cerebellar involvement.
-Insert table 1 here -
5.2 Strengths and limitations
The key strengths of this study are the use of both objective and subjective observational methods to 
assess stress related SLI, psychological and cognitive symptoms in this sample population. This will 
ensure a more complete understanding of the primary outcomes. Another key strength is that the 
patients will receive an expert opinion on their condition, providing benefit and hopefully encouraging 
study completion. 
There are however several limitations to the study. Firstly, the study is currently only based in a single 
NHS trust, limiting our knowledge of how the processes may work in other settings. However, it is 
anticipated that other NHS trusts will become involved as the study progresses. 
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Secondly, patients who are not able to complete self-administered questionnaires in English will be 
excluded as the questionnaires are only validated in English. In larger future studies, provisions for 
non-English speakers should be made.
Thirdly, the diagnosis of CD/FND can be complex and not always given on the basis of positive 
symptoms despite updated guidance (34), therefore our sample population may be particularly 
heterogeneous. Furthermore, given the potential various motor symptoms of the patients, it is 
anticipated that some patients may have difficulty with some procedures (e.g. hand tremors or vision 
problems may affect ability to complete questionnaires or certain cognitive tests). However, it is the 
purpose of the feasibility study to assess these issues.
5.3 Conclusion
This innovative, translational study explores stress-related SLI in CD/FND patients and the feasibility 
of an anticipated larger project aiming to develop new treatments for this vulnerable population. 
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Abbreviations
ACE Adverse Childhood Experience 
ANG2 Angiopoietin-2
CD Conversion Disorder
CRF Case Report Form
fMRI functional Magnetic Resonance Imaging
FND Functional Neurological Disorder
HCP Health Care Professional
hsCRP high sensitivity C-Reactive Protein 




IRAS Integrated Research Application System
miR-146a, miR-155, miR-223, miR-21, and miR-132 micro RiboNucleic Acid (microRNA)
NHS National Health Service
PTSD Post Traumatic Stress Disorder
REC Research Ethics Committee 
SAE Serious Adverse Event
SLI Systemic Low-grade Inflammation
TEWV Tees, Esk and Wear Valleys NHS Foundation Trust 
TNF Tumor Necrosis Factor
VEGF Vascular Endothelial Growth Factor
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Table 1. Table used by clinicians to enable the detailed description of the phenomenology from 
the perspective of possible cerebellar involvement in CD patients
Please specify: 
No movement possible Yes/NO
Abnormal Movement Yes/NO


















presenting complaint + history
psychiatric history 
medical history + medication
family history 











Ataxic dysartria Speech YES/NO
Swallowing YES/NO
Oculocerebellar dysfunction Visual disturbances 
YES/NO
Nystagmus YES/NO






MMSE Score and interpretation
Figure 1. Patient Eligibility Flowchart 
Figure 2. Patient Timeline Flowchart
